Thus, these results do not support a causal role of IL-23 signaling in NASH pathogenesis and suggest that targeting IL-23 signaling alone may not be a viable therapeutic strategy to treat NASH patients. Here, IL23A is linked to metabolic dysfunction-associated steatohepatitis.